Clinical Scorecard: Rising Endometrial Cancer Incidence: Clinical Priorities in Evaluation and Management

At a Glance

Key Highlights

• Any postmenopausal bleeding, including spotting, warrants evaluation.
• In premenopausal and perimenopausal patients, assess meaningful changes from baseline, including intermenstrual bleeding, increasingly heavy flow or postcoital bleeding.
• Initial assessment may include bleeding history, pelvic examination and transvaginal ultrasound; definitive diagnosis requires endometrial tissue sampling.
• Treatment intensity depends on histology and stage; early-stage disease may be treated with hysterectomy, while advanced disease may require multimodality treatment.
• Fertility-sparing approaches are described for carefully selected patients with certain early-stage endometrioid cancers and require close surveillance.

Guideline-Based Recommendations

Diagnosis

• Evaluate postmenopausal bleeding regardless of volume.
• Assess new or unexplained bleeding patterns in younger and perimenopausal patients rather than assuming they are due to hormonal transition.
• Use history, pelvic examination and transvaginal ultrasound as part of initial evaluation when appropriate; confirm diagnosis with endometrial tissue sampling.
• Consider family history suggestive of Lynch syndrome, including clustering of endometrial, colorectal and ovarian cancers; discuss genetic evaluation when indicated.

Management

• Use histology and stage to guide treatment intensity.
• Hysterectomy is central to treatment of early-stage disease; management of fallopian tubes and ovaries may vary with age and individual circumstances.
• Advanced disease may require surgery, radiation therapy, chemotherapy, immunotherapy or combinations of these approaches; biomarker-directed therapies and antibody-drug conjugates are also described.
• Discuss fertility-sparing options only for carefully selected patients with certain early-stage endometrioid cancers, with attention to oncologic safety and surveillance.

Monitoring & Follow-up

• Maintain close surveillance when a fertility-preserving approach is used.
• Continue evaluation when bleeding represents a meaningful change from the patient's baseline pattern.

Risks

• Risk factors highlighted include increasing age, obesity and comorbidities such as diabetes; prolonged estrogenic stimulation may contribute to endometrial cancer development.
• Most cases occur after menopause, but younger and perimenopausal patients with new or unexplained abnormal bleeding should remain in the differential assessment.
• Serous and clear cell histologies may behave more aggressively and may present at more advanced stages.
• Direct-to-consumer genetic testing may assess a more limited set of variants than comprehensive clinical testing.

Patient & Prescribing Data

The article discusses patients with suspected or diagnosed endometrial cancer, including postmenopausal patients with bleeding, younger patients with abnormal bleeding, patients with advanced disease and carefully selected patients considering fertility preservation.

No medication doses or prescribing regimens are provided. Treatment options described include surgery, radiation therapy, chemotherapy, immunotherapy, biomarker-directed therapies, antibody-drug conjugates and, for selected fertility-sparing cases, progesterone-based therapy including intrauterine delivery.

Clinical Best Practices

• Do not dismiss postmenopausal bleeding, even when limited to spotting.
• In premenopausal and perimenopausal patients, compare bleeding with the patient's baseline and evaluate meaningful changes.
• Do not presume abnormal bleeding is physiologic without appropriate assessment, while recognizing that most abnormal bleeding has a benign explanation.
• Obtain tissue sampling for definitive diagnosis; ultrasound assessment alone is not described as diagnostic.
• Individualize treatment according to histology, stage, age and clinical circumstances.
• When discussing fertility preservation, address patient selection, oncologic safety and close surveillance.
• Interpret family history and genetic testing in a clinical context; consider genetic evaluation when family clustering is suggestive.

Related Resources & Content

• Baptist HealthTalk discussion with John P. Diaz, M.D., as described in the supplied article